Influenza, pneumococcus and zoster NIP vaccine coverage recommended for adults, especially those medically at risk, is suboptimal. This study employs clinical decision support for Doctors and targeted recall in General Practice to increase coverage.
Several vaccines are funded for adults under the Australian National Immunisation Program (NIP), including influenza, pneumococcus and zoster. However, coverage of NIP vaccines recommended for adults, especially those medically at risk, is suboptimal.
UNSW is investigating the impact of using Topbar clinical decision support to opportunistically match under-vaccinated adults, and invite vaccination for patients eligible for influenza, pneumococcal and herpes zoster vaccines, during consultation. In parallel, the Pen CS’ Clinical Audit Tool (CAT4) is being employed to identify eligible unvaccinated patients in the practice to facilitate recall and reminder interventions by SMS voice and text messaging.
The aim is to increase coverage of NIP vaccines recommended for adults, especially those medically at risk. National vaccination coverage in those aged ≥65 years is approximately 75% for influenza and 55% for pneumococcal. For adults aged <65 years with medical risk factors, coverage is approximately 30%, for Aboriginal and Torres Strait Islander people aged ≥15 years influenza coverage is approximately 30%. These groups combined include >95% of Australians who have not received a vaccine for which they are eligible under the National Immunisation Program (NIP), or almost 4 million people.